Published in Vaccine on August 28, 2007
Viral etiology of severe pneumonia among Kenyan infants and children. JAMA (2010) 4.41
Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res (2011) 2.51
Incidence and severity of respiratory syncytial virus pneumonia in rural Kenyan children identified through hospital surveillance. Clin Infect Dis (2009) 2.22
Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A (2011) 2.08
The source of respiratory syncytial virus infection in infants: a household cohort study in rural Kenya. J Infect Dis (2013) 1.23
Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev Vaccines (2008) 1.23
Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol (2008) 1.22
Structural vaccinology starts to deliver. Nat Rev Microbiol (2012) 1.22
Live-attenuated respiratory syncytial virus vaccines. Curr Top Microbiol Immunol (2013) 1.10
Progress in the development of human parainfluenza virus vaccines. Expert Rev Respir Med (2011) 1.03
A highly attenuated recombinant human respiratory syncytial virus lacking the G protein induces long-lasting protection in cotton rats. Virol J (2010) 1.02
Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol (2013) 1.01
Increased genetic and phenotypic stability of a promising live-attenuated respiratory syncytial virus vaccine candidate by reverse genetics. J Virol (2012) 0.97
Pulmonary eosinophils and their role in immunopathologic responses to formalin-inactivated pneumonia virus of mice. J Immunol (2009) 0.96
Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate. J Virol (2015) 0.92
Brief History and Characterization of Enhanced Respiratory Syncytial Virus Disease. Clin Vaccine Immunol (2015) 0.92
Vaccine Induced Herd Immunity for Control of Respiratory Syncytial Virus Disease in a Low-Income Country Setting. PLoS One (2015) 0.90
Progress in respiratory virus vaccine development. Semin Respir Crit Care Med (2011) 0.89
Co-immunization with virus-like particle and DNA vaccines induces protection against respiratory syncytial virus infection and bronchiolitis. Antiviral Res (2014) 0.87
The secreted G protein of human respiratory syncytial virus antagonizes antibody-mediated restriction of replication involving macrophages and complement. J Virol (2012) 0.87
The association between age and the development of respiratory syncytial virus neutralising antibody responses following natural infection in infants. Vaccine (2014) 0.86
Vaccination against RSV: is maternal vaccination a good alternative to other approaches? Hum Vaccin Immunother (2013) 0.83
Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Viruses (2015) 0.83
Roadblocks to translational challenges on viral pathogenesis. Nat Med (2013) 0.82
Central role of dendritic cells in shaping the adaptive immune response during respiratory syncytial virus infection. Future Virol (2011) 0.81
Targeting RSV with vaccines and small molecule drugs. Infect Disord Drug Targets (2012) 0.81
Attenuation of live respiratory syncytial virus vaccines is associated with reductions in levels of nasal cytokines. J Infect Dis (2013) 0.80
Host proteome correlates of vaccine-mediated enhanced disease in a mouse model of respiratory syncytial virus infection. J Virol (2015) 0.79
Influence of Respiratory Syncytial Virus F Glycoprotein Conformation on Induction of Protective Immune Responses. J Virol (2016) 0.79
Absence of vaccine-enhanced RSV disease and changes in pulmonary dendritic cells with adenovirus-based RSV vaccine. Virol J (2011) 0.79
Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine. J Virol (2015) 0.78
A single amino acid in the F2 subunit of respiratory syncytial virus fusion protein alters growth and fusogenicity. J Gen Virol (2013) 0.78
Novel concepts in virally induced asthma. Clin Mol Allergy (2009) 0.78
A Recombinant Respiratory Syncytial Virus Vaccine Candidate Attenuated by a Low-Fusion F Protein Is Immunogenic and Protective against Challenge in Cotton Rats. J Virol (2016) 0.78
A live RSV vaccine with engineered thermostability is immunogenic in cotton rats despite high attenuation. Nat Commun (2016) 0.77
In Hot Pursuit of the First Vaccine Against Respiratory Syncytial Virus. Yonsei Med J (2016) 0.75
Pre-fusion F is absent on the surface of formalin-inactivated respiratory syncytial virus. Sci Rep (2016) 0.75
Quantification and determinants of the amount of respiratory syncytial virus (RSV) shed using real time PCR data from a longitudinal household study. Wellcome Open Res (2016) 0.75
Phosphorylation of Human Metapneumovirus M2-1 Protein Upregulates Viral Replication and Pathogenesis. J Virol (2016) 0.75
Development of a reverse genetics system for respiratory syncytial virus long strain and an immunogenicity study of the recombinant virus. Virol J (2014) 0.75
Ongoing developments in RSV prophylaxis: a clinician's analysis. Curr Opin Virol (2017) 0.75
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 49.00
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 10.85
An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol (1969) 6.85
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med (1998) 6.75
Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol (1969) 4.97
Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol (1969) 4.93
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis (2000) 2.90
Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol (1999) 2.80
A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med (2002) 2.34
Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis (2002) 2.19
Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol (2001) 1.95
Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis (1997) 1.86
Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology (1996) 1.60
Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics (1997) 1.51
A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology (1995) 1.46
Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc (2005) 1.42
Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res (1999) 1.34
Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes (1996) 1.32
The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis (2006) 1.30
Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med (2015) 5.86
Prospects for a dengue virus vaccine. Nat Rev Microbiol (2007) 4.99
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med (2002) 3.86
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol (2002) 3.74
Social justice and disadvantaged groups. Hastings Cent Rep (2007) 3.72
Normal and cystic fibrosis airway surface liquid homeostasis. The effects of phasic shear stress and viral infections. J Biol Chem (2005) 3.08
Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc Natl Acad Sci U S A (2012) 2.96
Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol (2005) 2.65
Genetic diversity between human metapneumovirus subgroups. Virology (2003) 2.65
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol (2010) 2.63
Dose-related effects of smallpox vaccine. N Engl J Med (2002) 2.55
Epidemiology, clinical presentation, and antibody response to primary infection with herpes simplex virus type 1 and type 2 in young women. Clin Infect Dis (2012) 2.55
A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial. J Infect Dis (2013) 2.51
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis (2005) 2.46
Risk factors for severe respiratory syncytial virus infection among Alaska native children. Pediatrics (2002) 2.46
Development of effective vaccines against pandemic influenza. Immunity (2006) 2.45
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med (2002) 2.34
The immunogenetics of smallpox vaccination. J Infect Dis (2007) 2.23
Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis (2002) 2.19
Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol (2005) 2.18
Liver disease and cirrhosis because of Khat chewing in UK Somali men: a case series. Liver Int (2010) 2.16
CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol (2009) 2.10
Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol (2005) 2.05
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol (2004) 2.03
The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol (2004) 2.02
Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J (2006) 1.98
Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season. MMWR Morb Mortal Wkly Rep (2014) 1.97
Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol (2008) 1.96
Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J (2006) 1.94
Poor immune responses to a birth dose of diphtheria, tetanus, and acellular pertussis vaccine. J Pediatr (2008) 1.93
Flow-cytometric detection of vaccinia-induced memory effector CD4(+), CD8(+), and gamma delta TCR(+) T cells capable of antigen-specific expansion and effector functions. J Infect Dis (2005) 1.84
The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial. Pediatr Infect Dis J (2013) 1.84
Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology (2004) 1.81
The definition of pneumonia, the assessment of severity, and clinical standardization in the Pneumonia Etiology Research for Child Health study. Clin Infect Dis (2012) 1.78
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol (2005) 1.72
Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis (2011) 1.71
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A (2004) 1.69
Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. Vaccine (2007) 1.67
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2015-16 Influenza Season. MMWR Morb Mortal Wkly Rep (2015) 1.64
A chimeric A2 strain of respiratory syncytial virus (RSV) with the fusion protein of RSV strain line 19 exhibits enhanced viral load, mucus, and airway dysfunction. J Virol (2009) 1.63
Complete genome sequence of avian paramyxovirus type 3 reveals an unusually long trailer region. Virus Res (2008) 1.63
Improved assay to detect neutralizing antibody following vaccination with diluted or undiluted vaccinia (Dryvax) vaccine. J Clin Microbiol (2003) 1.63
Response to smallpox vaccine in persons immunized in the distant past. JAMA (2003) 1.59
New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc (2005) 1.58
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58
Prevaccine determination of the expression of costimulatory B7 molecules in activated monocytes predicts influenza vaccine responses in young and older adults. J Infect Dis (2007) 1.56
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine (2009) 1.56
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology (2002) 1.55
Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53
Safety and efficacy of trivalent inactivated influenza vaccine in young children: a summary for the new era of routine vaccination. Pediatr Infect Dis J (2004) 1.52
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology (2003) 1.51
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine (2009) 1.51
Differential production of inflammatory cytokines in primary infection with human metapneumovirus and with other common respiratory viruses of infancy. J Infect Dis (2004) 1.51
Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology (2002) 1.51
A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J Virol (2003) 1.50
Molecular characterization and complete genome sequence of avian paramyxovirus type 4 prototype strain duck/Hong Kong/D3/75. Virol J (2008) 1.50
Comparative immunogenicity and efficacy of 13-valent and 7-valent pneumococcal conjugate vaccines in reducing nasopharyngeal colonization: a randomized double-blind trial. Clin Infect Dis (2013) 1.48
Respiratory syncytial virus infection sensitizes cells to apoptosis mediated by tumor necrosis factor-related apoptosis-inducing ligand. J Virol (2003) 1.48
The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses (2010) 1.47
Respiratory syncytial virus with the fusion protein as its only viral glycoprotein is less dependent on cellular glycosaminoglycans for attachment than complete virus. Virology (2002) 1.45
Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol (2006) 1.44
Genetic recombination during coinfection of two mutants of human respiratory syncytial virus. J Virol (2003) 1.44
Hypothalamic gene expression in ω-3 PUFA-deficient male rats before, and following, development of hypertension. Hypertens Res (2011) 1.43
Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. J Infect Dis (2004) 1.42
A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults. J Infect Dis (2009) 1.40
Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J (2007) 1.39
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine (2013) 1.39
Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens. Proc Natl Acad Sci U S A (2007) 1.39
Laboratory methods for determining pneumonia etiology in children. Clin Infect Dis (2012) 1.38